These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
280 related articles for article (PubMed ID: 32356859)
41. ADAMTS13-specific circulating immune complexes as potential predictors of relapse in patients with acquired thrombotic thrombocytopenic purpura. Mancini I; Ferrari B; Valsecchi C; Pontiggia S; Fornili M; Biganzoli E; Peyvandi F; Eur J Intern Med; 2017 Apr; 39():79-83. PubMed ID: 27887777 [TBL] [Abstract][Full Text] [Related]
42. How I treat immune-mediated thrombotic thrombocytopenic purpura after hospital discharge. Akwaa F; Antun A; Cataland SR Blood; 2022 Aug; 140(5):438-444. PubMed ID: 35667044 [TBL] [Abstract][Full Text] [Related]
43. Peak ADAMTS13 activity to assess ADAMTS13 conformation and risk of relapse in immune-mediated thrombotic thrombocytopenic purpura. Prasannan N; Dragunaite B; Subhan M; Thomas M; de Groot R; Singh D; Vanhoorelbeke K; Scully M Blood; 2024 Jun; 143(25):2644-2653. PubMed ID: 38502824 [TBL] [Abstract][Full Text] [Related]
44. ADAMTS13 and anti-ADAMTS13 antibodies as markers for recurrence of acquired thrombotic thrombocytopenic purpura during remission. Peyvandi F; Lavoretano S; Palla R; Feys HB; Vanhoorelbeke K; Battaglioli T; Valsecchi C; Canciani MT; Fabris F; Zver S; Réti M; Mikovic D; Karimi M; Giuffrida G; Laurenti L; Mannucci PM Haematologica; 2008 Feb; 93(2):232-9. PubMed ID: 18223285 [TBL] [Abstract][Full Text] [Related]
45. Generation of anti-idiotypic antibodies to detect anti-spacer antibody idiotopes in acute thrombotic thrombocytopenic purpura patients. Schelpe AS; Roose E; Joly BS; Pareyn I; Mancini I; Biganzoli M; Deckmyn H; Voorberg J; Fijnheer R; Peyvandi F; De Meyer SF; Coppo P; Veyradier A; Vanhoorelbeke K Haematologica; 2019 Jun; 104(6):1268-1276. PubMed ID: 30523052 [TBL] [Abstract][Full Text] [Related]
46. Co(III)-NTA Mediated Antigen Immobilization on a Fiber Optic-SPR Biosensor for Detection of Autoantibodies in Autoimmune Diseases: Application in Immune-Mediated Thrombotic Thrombocytopenic Purpura. Horta S; Qu JH; Dekimpe C; Bonnez Q; Vandenbulcke A; Tellier E; Kaplanski G; Delport F; Geukens N; Lammertyn J; Vanhoorelbeke K Anal Chem; 2020 Oct; 92(20):13880-13887. PubMed ID: 32929962 [TBL] [Abstract][Full Text] [Related]
47. Predictors of relapse and preventative strategies in immune thrombotic thrombocytopenic purpura. Pavenski K; Huang SS; Patriquin CJ Expert Rev Hematol; 2021 Nov; 14(11):1027-1040. PubMed ID: 34747320 [TBL] [Abstract][Full Text] [Related]
49. Plasma Levels of Big Endothelin-1 Are Associated with Renal Insufficiency and In-Hospital Mortality of Immune Thrombotic Thrombocytopenic Purpura. Lu R; Zheng XL Thromb Haemost; 2022 Mar; 122(3):344-352. PubMed ID: 33984867 [TBL] [Abstract][Full Text] [Related]
50. [Endothelial dysfunction in thrombotic thrombocytopenic purpura: therapeutic perspectives]. Prevel R; Roubaud-Baudron C; Tellier E; Le Besnerais M; Kaplanski G; Veyradier A; Benhamou Y; Coppo P; Rev Med Interne; 2021 Mar; 42(3):202-209. PubMed ID: 33455838 [TBL] [Abstract][Full Text] [Related]
51. When targeted therapies alleviate the burden of TPE: The example of immune-mediated TTP. Picod A; Coppo P Transfus Apher Sci; 2019 Jun; 58(3):273-277. PubMed ID: 31018909 [TBL] [Abstract][Full Text] [Related]
52. The standard of care for immune thrombotic thrombocytopenic purpura today. Zheng XL J Thromb Haemost; 2021 Aug; 19(8):1864-1871. PubMed ID: 34060225 [TBL] [Abstract][Full Text] [Related]
53. Relapse Rate in Survivors of Acute Autoimmune Thrombotic Thrombocytopenic Purpura Treated with or without Rituximab. Falter T; Herold S; Weyer-Elberich V; Scheiner C; Schmitt V; von Auer C; Messmer X; Wild P; Lackner KJ; Lämmle B; Scharrer I Thromb Haemost; 2018 Oct; 118(10):1743-1751. PubMed ID: 30235478 [TBL] [Abstract][Full Text] [Related]
54. Interrelationship between ADAMTS13 activity, von Willebrand factor, and complement activation in remission from immune-mediated trhrombotic thrombocytopenic purpura. Wu H; Jay L; Lin S; Han C; Yang S; Cataland SR; Masias C Br J Haematol; 2020 Apr; 189(1):e18-e20. PubMed ID: 32065383 [No Abstract] [Full Text] [Related]
55. N-glycan-mediated shielding of ADAMTS13 prevents binding of pathogenic autoantibodies in immune-mediated TTP. Ercig B; Graça NAG; Kangro K; Arfman T; Wichapong K; Hrdinová J; Kaijen P; van Alphen FPJ; van den Biggelaar M; Vanhoorelbeke K; Veyradier A; Coppo P; Reutelingsperger C; Nicolaes GAF; Männik A; Voorberg J Blood; 2021 May; 137(19):2694-2698. PubMed ID: 33544829 [TBL] [Abstract][Full Text] [Related]
56. Medical consult: aHUS, TTP? How to distinguish and what to do. Story CM; Gerber GF; Chaturvedi S Hematology Am Soc Hematol Educ Program; 2023 Dec; 2023(1):745-753. PubMed ID: 38066937 [TBL] [Abstract][Full Text] [Related]